Astrazeneca and University of Cambridge Partner on Neurodegenerative Disease Research

Astrazeneca, together with its biologics arm, Medimmune, has expanded its strategic alliance with University of Cambridge beyond oncology into research and development for neurodegenerative diseases. The focus of the joint projects will be on biomarkers, drug discovery and personalized medicine. The partnership merges the expertise of world class researchers from the University of Cambridge with drug development expertise and experimental tools from Astrazeneca and Medimmune. As part of the collaboration, Astrazeneca will also share proprietary compounds in its development pipeline, such as mTOR and AKT inhibitors, to potentially identify new uses of these drugs. Hopefully, advances from these projects will also lead to new targets and candidate biomarkers for ALS.

Astrazeneca, together with its biologics arm, Medimmune, has expanded its strategic alliance with University of Cambridge beyond oncology into research and development for neurodegenerative diseases. The focus of the joint projects will be on biomarkers, drug discovery and personalized medicine. The partnership merges the expertise of world class researchers from the University of Cambridge with drug development expertise and experimental tools from Astrazeneca and Medimmune. As part of the collaboration, Astrazeneca will also share proprietary compounds in its development pipeline, such as mTOR and AKT inhibitors, to potentially identify new uses of these drugs. Hopefully, advances from these projects will also lead to new targets and candidate biomarkers for ALS.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail